Get started
Author

Dennis Juarez

Targeting the Mevalonate Pathway in Cancer
2021 · Dennis Juarez, David A. Fruman · Trends in cancer · 160
Statins enhance efficacy of venetoclax in blood cancers
2018 · J. Scott Lee, Andrew Roberts, et al. · Science Translational Medicine · 92
Inhibition of toxic IAPP amyloid by extracts of common fruits
2014 · Pei-Yu Kao, Evangeline Green, et al. · Journal of Functional Foods · 16
PDF
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al. · Cancer Research Communications · 14
PDF
A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy
2024 · Elizabeth A. Brem, Kevin Shieh, et al. · Blood Neoplasia · 10
Iron Overload in Dialysis Patients: Serum Ferritin Underestimates Liver Iron Measured By MRI
2023 · Christopher Grant, Dennis Juarez, et al. · Blood · 2
PDF
Pitavastatin Potentiates Mitochondrial Dysfunction and Venetoclax Cytotoxicity in Acute Myeloid Leukemia Cells
2024 · Madhuri Paul, Roberta Buono, et al. · Blood · 1
Table S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al. · 1
Intracellular Staining of PUMA in Primary PBMC Lymphocytes v1
2023 · Dennis Juarez, dfruman not provided · 1
PDF
Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia
2026 · Roberta Buono, Dennis Juarez, et al. · Blood Neoplasia
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer
2025 · Alica K. Beutel, Sabrina Calderon, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract C052: Repurposing Statins to Target Gemcitabine Resistance in Pancreatic Cancer
2024 · Sabrina Calderon, Alica K. Beutel, et al. · Cancer Research
Abstract A056: Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer
2024 · Alica K. Beutel, Sabrina Calderon, et al. · Cancer Research
FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
Data from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
Figure S1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
PDF
Figure S10 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
Figure S1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 6 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 6 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023 · Dennis Juarez, Roberta Buono, et al.
Works count: 81
Citation count: 297
H-index: 5
I10-index: 5
Year
Topic
Type